title: Effect of low molecular weight heparin rectal suppository on experimental ulcerative colitis in mice.
abstract: The objective of this study was to investigate the effect and possible mechanism of rectally administered low molecular weight heparin (LMWH) on experimental ulcerative colitis. LMWH rectal suppository was prepared and its efficacy was studied by macroscopical and histological scoring systems as well as myeloperoxidase activity. Serum levels, including tumor necrosis factor-α (TNFα), interleukin-6 (IL-6) and a link factor of blood coagulation and inflammation factor Xa (FXa) were assayed by enzyme-linked immunosorbent assay. The expression of Musashi-1 (as an intestinal stem cell marker) in the colons was assessed by immunohistochemical analysis. The results showed that LMWH rectal suppository significantly decreased serum levels of TNF-α, IL-6 as well as FXa, while increased the expression of Musashi-1 in colon compared with acetic acid induced ulcerative colitis model group. All these preliminary results indicate LMWH rectal suppository is promising for treatment of ulcerative colitis.
authors.affiliation: Institute of Biochemical and Biotechnological Drugs, Shandong University, 44,Wenhua Xilu, Jinan 250012, China.
authors.forename: Junyong
authors.initials: J
authors.lastname: Luo
authors.forename: Jichao
authors.initials: J
authors.lastname: Cao
authors.forename: Xueliang
authors.initials: X
authors.lastname: Jiang
authors.forename: Huifei
authors.initials: H
authors.lastname: Cui
mesh_terms: D000285:Administration, Rectal; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D003106:Colon / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D016207:Cytokines / Q000097:blood; D015951:Factor Xa / Q000032:analysis; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage* / Q000494:pharmacology* / Q000627:therapeutic use; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D051379:Mice; D009195:Peroxidase / Q000032:analysis; D011092:Polyethylene Glycols; D013488:Suppositories; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016207:Cytokines; D006495:Heparin, Low-Molecular-Weight; D015850:Interleukin-6; D013488:Suppositories; D014409:Tumor Necrosis Factor-alpha; D011092:Polyethylene Glycols; D009195:Peroxidase; D015951:Factor Xa